Press Releases

First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c Company to host conference call and

Naim Alkhouri , MD, FAASLD, to Present Findings from Non-alcohol Related Fatty Liver Disease Feasibility Study SAN FRANCISCO --(BUSINESS WIRE)--Jun. 16, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated,

On track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO --(BUSINESS WIRE)--May 11, 2023-- Better Therapeutics, Inc.

SAN FRANCISCO --(BUSINESS WIRE)--May 4, 2023-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today

SAN FRANCISCO --(BUSINESS WIRE)--Apr. 6, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases,

Advanced preparations for potential commercial launch of BT-001 in U.S. in mid-2023 Reported positive topline results   from exploratory trial for fatty liver disease Announced restructuring and other cost saving actions to extend financial runway Company to host conference call and webcast today

SAN FRANCISCO --(BUSINESS WIRE)--Mar. 23, 2023-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today

SAN FRANCISCO --(BUSINESS WIRE)--Feb. 9, 2023-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today

Study Conducted with Arizona Liver Health Met Primary Endpoint and Established Proof-of-Concept for Prescription Digital Therapy Platform to Improve Disease Biomarkers in NAFLD and NASH Patients Company Intends to Apply for Breakthrough Device Designation with FDA Company to Host Conference Call

SAN FRANCISCO --(BUSINESS WIRE)--Dec. 2, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that the compensation committee of